Study Design: Systematic review. Objective: To evaluate the impact of riluzole on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic spinal cord injury (SCI).
Introduction
Nontraumatic and traumatic injuries to the spinal cord initiate a cascade of pathophysiological changes that may impair normal motor, sensory, and autonomic functions and cause irreversible tissue damage.
1,2 Surgical intervention is recommended as the preferred treatment strategy for patients with moderate to severe degenerative cervical myelopathy (DCM) as it can halt neurologic decline and significantly improve functional impairment, disability, and quality of life. 3, 4 Furthermore, early surgical management of traumatic spinal cord injury (SCI) is increasingly prioritized due to emerging evidence that patients decompressed and stabilized within 24 hours of injury exhibit superior outcomes. 5, 6 There is also an opportunity to explore adjuvant treatments for the management of traumatic and nontraumatic SCI, including pharmacological strategies. Compression of the spinal cord alters its micro-and macro-vasculature, results in ischemia, and disturbs ionic homeostasis through the activation of voltagegated sodium channels. 7 An influx of sodium results in cellular swelling, edema, and an increase in the activity of the sodiumcalcium exchanger on the neuronal cell membrane. 8 Calcium entry pre-synaptically triggers the release of glutamate, which causes excitotoxicity and neuronal death. A neuroprotective drug such as riluzole may be effective at halting this cascade and preserving the structural integrity of the spinal cord.
Riluzole has neuroprotective, anti-ischemic, and antiepileptic properties as well as several proposed mechanisms of action. 9 Specifically, it is a sodium channel blocker, a regulator of glutamate release, an antagonist at both NMDA and non-NMDA receptors, and an inhibitor of GABA reuptake. [10] [11] [12] Randomized controlled trials have demonstrated that riluzole increases survival, decreases the necessity for tracheostomy, and attenuates muscle deterioration in patients with amyotrophic lateral sclerosis. 13, 14 Riluzole has also demonstrated promising results in other neurological conditions, including Huntington's disease, cerebellar ataxia, and cervical SCI. [15] [16] [17] [18] Furthermore, in vitro studies have indicated that riluzole significantly improves axonal conduction, prevents cellular necrosis and apoptosis, and enhances nerve fiber regeneration. 19 Given its mechanism of action and the cellular changes that follow compression of the spinal cord, there may be a role for riluzole as an adjuvant therapy in the management of DCM and SCI.
This systematic review aims to evaluate the impact of riluzole on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic SCI. This review serves as an initial step in evaluating the suitability of riluzole for the management of DCM and SCI. Table 1 provides a detailed summary of the inclusion and exclusion criteria for this review.
Methods

Eligibility Criteria
Population and Injury Model
This review targeted studies on animal models (eg, rats, mice, rabbits, primates) of traumatic and nontraumatic SCI. Studies were excluded if they consisted of humans or if the animal model mimicked root avulsion or peripheral nerve injuries, traumatic brain injury, epilepsy, Parkinson's disease, or amyotrophic lateral sclerosis.
Intervention and Comparison
The intervention of interest was riluzole, injected intravenously, intraperitoneally, intrathecally, or intracerebroventricularly. There were no limitations on the dosing, timing of administration, or duration of treatment. Studies were only included if they had a control group (eg, vehicle injection) and 
Outcomes
This review primarily focused on neurobehavioral outcomes such as the Basso, Beattie, Besnahan (BBB) locomotor score, the inclined board test, the von Frey filament test, beam balance, gait assessment, and grip strength. Studies were excluded if they only discussed autonomic function or physiological parameters (eg, bladder function, heart rate, blood pressure) or if they evaluated in vitro changes (eg, oxidative damage, microglial activation, axonal loss) following riluzole administration.
Information Sources
A systematic search was conducted of MEDLINE, MEDLINE In-Process, and EMBASE to identify relevant studies. The search was completed on November 13, 2017.
Search Strategy
A search strategy was constructed with the assistance of a librarian at the Toronto Western Hospital. The strategy was originally prepared in MEDLINE and then appropriately modified for EMBASE. The terms used to search both databases are provided in Appendix A, available online. Only studies involving animal models of spinal pathologies and in English were considered for inclusion, with no other limits applied.
Study Selection
Duplicates, conference proceedings, editorials, and reviews were first excluded in Endnote. The remaining abstracts were reviewed independently by 2 of the authors and sorted based on predefined inclusion criteria (MZ and LT). In some cases, full text investigation was required to clarify whether the study was relevant. Discussion was used to resolve disagreement between reviewers.
Data Extraction and Synthesis
The following data were extracted from each article: author, year and location of investigation; sample characteristics, including sample size, type and weight of animals, and level of injury; injury model; intervention, including dose and route of drug administration; outcomes evaluated and timing of assessment; and statistical methods. Main study conclusions were also extracted if they highlighted the impact of riluzole on neurobehavioral outcomes compared to controls.
Assessment of Risk of Bias and Study Quality
The risk of bias of each study was evaluated using the SYRCLE tool (Systematic Review Center for Laboratory Animal Experimentation). 20 This checklist, presented in Table 2 , was adopted from the Cochrane Collaboration risk of bias tool and modified to encompass certain biases that are relevant to animal experiments. It consists of 10 domains related to 6 types of bias: selection, performance, detection, attrition, reporting, and other biases. 20 Signaling questions provided by Hooijmans et al were used to assist in judging whether the experiment had a low, moderate, or high risk of bias for each entry. 20 The authors of this study also recommended not to compute a summary score as that would involve assigning weights to each domain.
Reporting
This review was formatted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. 21 
Results
Study Selection
The search yielded a total of 3180 unique citations. Using Endnote, 1799 articles were excluded because they were either not in English (n ¼ 196) or were conference proceedings, editorials, literature reviews, or commentaries (n ¼ 1603). After review of the remaining titles and abstracts, 1340 studies did not meet the inclusion criteria. Following full text investigation, an additional 25 studies were excluded; reasons for 
Study Characteristics
Sixteen studies evaluated the impact of riluzole on neurobehavioral outcomes in either rat (n ¼ 14) 9, 10, 12, 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] or rabbit (n ¼ 2)
11,32 models of spinal cord pathology. Injury models included acute SCI via weight dropping, micro-scissors, or vascular clips (n ¼ 9) 9, 12, 19, 22, 24, [27] [28] [29] [30] ; DCM through progressive compression of the cord (n ¼ 2) 26, 33 ; and spinal cord ischemia via occlusion of the aorta (n ¼ 5). 10, 11, 25, 31, 32 Of the models of acute SCI, 4 were at the thoracic level, 3 were cervical, 2 were cervicothoracic (C7-T1), and 1 was sacral. The most commonly assessed outcome measures were BBB locomotor score (n ¼ 7) and gait analysis (n ¼ 4). Table 3 summarizes the tools used to evaluate outcomes. Table 4 provides an overview of the included studies.
Risk of Bias
The SYRCLE tool evaluated risk of bias across studies. In the majority of studies, allocation sequence was adequately generated, applied (n ¼ 16), and concealed (n ¼ 15). Fifteen studies randomly selected animals for outcome assessment. Investigators were blinded from the intervention in 6 studies and outcome assessors were blinded in 11 studies. Animals were randomly housed during the experiment in only 6 studies and incomplete outcome data was only addressed in 3 studies.
Finally, it was unclear whether outcomes were selectively reported in any of the studies (Appendix C).
What Is the Impact of Riluzole on Neurobehavioral Outcomes?
The main results are summarized in Table 5 .
Basso, Beattie, Besnahan Locomotor Score. Six studies evaluated the impact of riluzole on BBB locomotor scores in rats with SCI. 12, 19, 22, 27, 29, 30 In a study by Hosier et al, rats treated with riluzole exhibited significantly higher BBB scores than controls in both the ipsilateral and contralateral limbs at 6 weeks following injury. 22 Vasconcelos et al also demonstrated improved BBB scores in a riluzole group at 1 and 2 weeks postinjury, but not at 3 or 4 weeks. 30 Furthermore, only rats in the riluzole group were able to achieve plantar weight support at 3 weeks. In a third study, rats treated with 8 mg/kg riluzole intraperitoneally at 1 and 3 hours after injury exhibited significant improvements in BBB score compared to controls at 2 to 6 weeks following injury. 19 However, only rats administered with riluzole 1 hour after injury demonstrated significant improvement on the BBB subscores. In contrast, 3 studies indicated no association between BBB score and riluzole administration in preclinical models of SCI. 12, 27, 29 A single study by Wu et al examined BBB score and subscores in rats treated with riluzole 4 hours after occlusion of the aorta. 31 Based on their results, riluzole preserved function at 1 and 5 days following ischemia. Furthermore, rats treated with riluzole had significantly higher stepping and coordination subscores than controls.
Von Frey Filament. Four studies assessed sensitivity to innocuous mechanical stimulation using von Frey filament testing. 12, 19, 26, 33 In a study by Haman and Sagen, riluzole administered intraperitoneally significantly increased withdrawal thresholds at 60, 90, and 120 minutes posttreatment. 12 Furthermore, intracerebroventricular injection of riluzole increased withdrawal thresholds in a dosedependent manner. 12 In contrast, lower doses of intraperitoneal riluzole (0.8 or 2.5 mg/kg) or riluzole administered intrathecally did not affect the response to mechanical stimuli. A second study by Moon et al also demonstrated increased withdrawal thresholds in both paws in rats treated intraperitoneally with riluzole. 26 Furthermore, a combination of decompression surgery and riluzole was superior at attenuating mechanical allodynia as compared to decompression alone. 33 Finally a study by Wu et al failed to identify significant differences in response to mechanical stimuli between rats injected with riluzole and controls. 19 Tail Flick. Three studies assessed thermal hyperalgesia using the tail flick test. 12, 26, 33 Intraperitoneal injection of riluzole significantly increased tail flick latency compared with controls. 12, 26 Furthermore, rats receiving a combination of surgical decompression and riluzole had significantly reduced thermal allodynia compared with decompression alone. 33 There were, however, no significant changes in latencies between controls and rats receiving intrathecal or intracerebroventricular riluzole. 12 Tarlov Score. Three studies evaluated the impact of riluzole on Tarlov scores. 10, 11, 32 Based on their results, rats receiving riluzole exhibited significantly improved Tarlov scores compared with controls. Furthermore, the incidence of complete paraplegia, defined as a Tarlov score of 0, was significantly lower in rats treated with riluzole. 11 In contrast, the incidence of paraparesis, defined as a Tarlov score of 1, 2, or 3, was not significantly different between riluzole and control groups. 11 Furthermore, results from the study by Lang-Lazdunski et al Assesses hindpaw movement and weight bearing, coordination of the hindlimb with the forelimbs, and placement of trunk and tail. Scores range from 0 to 21, where 0 is a complete lack of hindlimb movement and 21 is normal function. Angle Board Test/Inclined plane 9, 22, 29 Maximum angle at which an animal can support its weight on an inclined plane (up-and/or down-angled) for 5 seconds; measured from 0 to 90 . von Frey filament test 12, 19, 26 Assesses sensitivity to innocuous mechanical stimulation. A von Frey filament is applied to the skin of the hindpaw or forepaw and a withdrawal reaction is observed. If no reaction is elicited, then a higher force filament is used. The smallest filament that elicits a response is considered the threshold stimulus. Tail flick test 12, 26 Assesses thermal hyperalgesia. A circle of light is applied to the dorsal tail. The tail flick withdrawal latency is the time between application of the radiant heat stimulus and withdrawal of the tail from the light. Beam Balance 22 0, falls off; 1, hangs on; 2, stands on beam but one or two legs slip off; 3, stands on beam; 4, walks on beam. Accelerating rotarod 22 Accelerating rod, starting at 4 rpm and increasing at a rate of 2 rpm every 5 seconds to a maximum of 45 rpm. Gait analysis 19, 26, 28, 33 Swing phase duration, swing speed, paw intensity, paw print width, paw print length, stride length, stance phase, 4-limb support, print positions, forepaw initial contact. Grip strength 28 Animals are allowed to grasp a bar. They are then pulled away parallel to the degree they grasped at until they release the bar. Grip force is measured. Tarlov scale 10, 11, 32 0, no movement; 1, slight movement; 2, sits with assistance; 3, sits alone; 4, weak hop; 5, normal hop OR 0, paraplegic with no lower extremity function; 1, poor lower extremity function, weak antigravity movement only; 2, some lower extremity motor function with good antigravity strength but inability to draw legs under body or hop; 3, ability to draw legs under body and hop but not normally; 4, normal motor function. Paw placement test 28 Forelimb activity during exploration in a cylinder. The number of times the animals places its ipsilateral or contralateral forelimb or both is recorded. Swimming test 30 Animal swimming velocity is recorded in a circular pool over a duration of 2 minutes. Activity box test The animals were observed in an open field for at least 1 minute; 0, no movement of the hindlimbs; 1, barely perceptible movement of hindlimbs; 2, brisk movements at most hindlimb joints in one or both limbs but no coordination or weight support; 3, alternative stepping and propulsive movements of hindlimbs but no weight support; 4, can support weight on hindlimbs; 5, walks with only mild deficit; 6, normal walking. Motor scores 22, 25 0, no movement of hindlimbs, no weight bearing; 1, barely perceptible movements of hindlimbs, no weight bearing; 2, frequent and/or vigorous movement of hindlimbs but no weight support; 3, alternative stepping and propulsive movements of hindlimbs, some intermittent weight bearing; 4, can support weight and walk with deficit apparent; 5, normal walking. Motor sensory deficit index (MSDI) 25 Walking with lower extremities: 0, normal; 1, toes flat under body when walking but ataxia is present; 2, knuckle walking; 3, movements in lower extremities but unable to knuckle walk; 4, no movement, drags lower extremities. Pain sensation: 0, normal, withdrawal to toe pinch; 1, squeals to toe pinch but does not withdraw; 2, no reaction to toe pinch. MSDI is a summation of walking with lower extremities and pain sensation. There were no significant differences in arousal scores and motor scores between the control and riluzole groups (P > .05, day 7 after trauma). Ipsilateral and contralateral modified BBB scores were significantly higher in rats receiving riluzole than controls (P < .05, week 6 after trauma). Time on accelerating rotarod was significantly longer in rats receiving riluzole than controls (P < .05, week 6 after trauma). There were no significant differences in inclined plane angle and beam balance scores between the control and riluzole groups (P > .05, week 6 after trauma).
Karadimas et al (2015)
33
One-way ANOVA with Tukey post hoc A combination of surgical decompression and riluzole administration resulted in longer forelimb stride length, higher regularity index and shorter forepaw initial contact than decompression alone (P < .05, 1 week after surgery). Forelimb stance phase, percentage 4-limb support and print positions did not differ between decompression only and decompression plus riluzole groups (P > .05, 1 week after surgery). A combination of surgical decompression and riluzole administration resulted in a shorter stance phase, longer stride length, stronger handgrip and decreased print positions than decompression alone (P < .05, 12 weeks after surgery). On von Frey filament testing, a combination of surgical decompression and riluzole significantly increased withdrawal thresholds in the hindpaw compared to decompression only (P < .05, 12 weeks after surgery). Rats receiving a combination of surgical decompression and riluzole had significantly increased tail withdrawal latency compared to rats treated with only decompression at 12 weeks (P < .05).
Kitzman (2009) 24
Kruskal-Wallis test Dunn's multiple comparison tests
Rats receiving riluzole 8mg/kg had a significantly decreased response to light touch (1 hour but not 3, 6, and 12 hours post-injection) and pinch (1 and 3 hours but not 6 and 12 hours post-injection) compared to controls (P < .05). Rats receiving riluzole 10 mg/kg had a significantly decreased response to light touch, stretch and pinch compared to controls at 1 and 3 hours but not 6 and 12 hours postinjection (P < .05).
Lang-Lazdunski et al (2000)
25
Kruskal-Wallis test Mann-Whitney U tests MSDI scores were significantly better in the riluzole group than in the control group at 24 (P ¼ .0001), 48 (P ¼ .0002), and 96 hours (P ¼ .009) after reperfusion Lang-Lazdunski et al (2000) 32
Kruskal-Wallis tests Mann-Whitney U tests Modified Tarlov scores were significantly better in the riluzole and the riluzole with MgSO 4 groups than in the MgSO 4 only and control groups (P < .01).
(continued) Mann-Whitney U tests Tarlov scores were significantly better in the riluzole group than in the control group, regardless of dose and timing of administration (P < .001, 24 hours after ischemia). Rats receiving riluzole 4 mg/kg i.v. 30 minutes before ischemia and at the onset of reperfusion achieved significantly better Tarlov scores than rats treated with riluzole 8 mg/kg i.v. only at the onset of reperfusion (P ¼ .00 444, 24 hours after ischemia). Tarlov scores did not significantly differ between rats treated with riluzole 8 mg/kg i.v. 30 minutes before ischemia and those receiving riluzole 4 mg/kg i.v. 30 minutes before ischemia as well as at the onset of reperfusion (P ¼ .2004, 24 hours after ischemia).
Lips et al (2000) 11
Fishers exact test Rats receiving riluzole exhibited a significant decrease in the incidence of complete paraplegia (48 and 72 hours) and improved Tarlov scores compared with controls (P < .05).
Incidence of paraparesis was not significantly different between riluzole and control groups at any time point assessed (P > .05).
Moon et al (2014) 26
One-or 2-way ANOVA with Bonferroni correction t Tests
On von Frey filament testing, riluzole significantly increased withdrawal thresholds in both the forepaw (2, 6, 7, and 8 weeks) and hindpaw (3 to 8 weeks) compared to the control group (P < .05). Riluzole significantly increased tail withdrawal latency compared to the control group at 8 weeks (P < .05). Rats in the riluzole group had significantly shorter forelimb and hindlimb swing phases, greater forepaw and hindpaw intensity, and faster hindlimb swing speed than the control group at 8 weeks (P < .05).
Mu et al (2000)
27 Two-way ANOVA Fishers test
There were no significant differences in BBB open field locomotor scores between the riluzole and control group at any assessment point (P > .05).
Rats receiving a combined administration of riluzole and MP exhibited higher BBB open field locomotor scores than controls at 4, 5, and 6 weeks (P < .05).
Satkunendrarajah et al (2016) 28
One-or 2-way ANOVA with Bonferroni correction t Test
Rats in the riluzole group had significantly increased ipsilateral forelimb grip strength (3 to 43 days post-surgery) and contralateral forelimb grip strength (23 to 43 days postsurgery) compared to the control group (P < .01). Rats in the riluzole group had significantly faster swing speeds and longer ipsilateral stride lengths compared to the control group at 2 (P < .005, P < .001) and 4 weeks (P < .05, P < .008) post-surgery but not at 6 weeks. Rats in the riluzole group had significantly increased ipsilateral forepaw print width during stance phase and longer ipsilateral forepaw print length (2, 4, and 6 weeks post-injury) compared to the control group (P < .05). Print length and width of the contralateral forepaw were not significantly different between groups. Rats in the riluzole group had a significantly higher percentage of ipsilateral paw placements (2, 4, and 6 weeks post-injury) than the control group. Rats treated with riluzole exhibited higher inclined plane scores than controls at 1, 2, 3, 4, and 6 weeks following injury (P < .05). There were no significant differences in BBB locomotor scores between the riluzole and the control group at any assessment point (P > .05).
Vasconcelos et al (2016) 30
One-way or 2-way ANOVA with post-hoc Bonferroni test
Rats treated with riluzole achieved significantly higher BBB sores than controls at 1 and 2 weeks post-injury (P < .05) but not at 3 and 4 weeks post-injury. There were no differences in BBB scores between the control group and the combined riluzole and MgSO 4 group. Rats treated with riluzole traveled a significantly longer distance than controls at 29 days post-injury (P < .05). There were no differences in distance traveled between the control group and the combined riluzole and MgSO 4 group. There were no significant differences in swimming velocities between the riluzole and control groups.
Wu et al (2013) 19 Rats treated with riluzole (8 mg/kg 1 and 3 hours after injury) achieved significantly higher BBB scores than controls at 2 to 6 weeks after injury (P < .05).
(continued)
indicated that riluzole given before ischemia is more effective than riluzole injected at the onset of reperfusion.
10
Gait Analysis and Grip Strength. Gait analysis was performed in 4 studies. 19, 26, 28, 33 Compared with controls, riluzole resulted in significantly shorter limb swing phases; greater paw pressure; longer ipsilateral stride length, print width during stance phase and print length; reduced number of footfalls; and a higher percentage of ipsilateral paw placements. 19, 26, 28 Print length and width of the contralateral forepaw, however, did not significantly differ between riluzole and control groups. 28 In a study by Karadimas et al, a combination of surgical decompression and riluzole resulted in longer forelimb stride length, higher regularity index, shorter forepaw initial contact, shorter stance phase, stronger hand grip, and decreased print positions than decompression alone. 33 Finally, ipsilateral and contralateral grip strength were significantly higher in rats treated with riluzole than controls. 28 Inclined Plane Scores. Three studies assessed the association between riluzole and inclined plane scores. 9, 22, 29 In a study by Schwartz and Fehlings, rats treated with riluzole exhibited higher inclined plane scores than controls at 1 to 4 and 6 weeks following injury. 29 This positive finding was confirmed by Ates et al. 9 In contrast, the study by Hosier et al did not detect significant differences in inclined plane scores between the control and riluzole groups in a model of unilateral cervical SCI. 22 Other Measures. Based on single studies, rats receiving riluzole exhibited significantly longer time on accelerating rotarod, improved motor sensory deficit index, and a longer distance traveled on an activity test than controls. 22, 25, 30 Furthermore, a study by Kitzman demonstrated that rats receiving 10 mg/kg of riluzole had a significantly decreased response to light touch, stretch, and pinch compared with controls at 1 and 3 hours, but not at 6 and 12 hours, post injection. 24 In contrast, single studies identified no association between treatment with riluzole and beam balance scores or swimming velocities.
22,30
Discussion
This systematic review aims to evaluate the association between riluzole and neurobehavioral outcomes in preclinical models of traumatic and nontraumatic SCI. Based on the results, riluzole has a significant impact on locomotor scores, gait parameters, and measures of hyperalgesia and mechanical allodynia.
The most common outcome assessment tool used across studies was the BBB locomotor score, which was originally designed to evaluate midline thoracic injuries. 22 Other tests were also conducted to assess upper extremity function in isolation as well as coordination of the forelimbs and hindlimbs; these included grip strength, accelerating rotarod, and beam balance. 22, 28 As summarized by this review, riluzole significantly improved motor recovery, locomotion, and functional outcomes in a variety of animal models of traumatic and nontraumatic SCI. Potential explanations for these results include (1) sparing of serotonergic and glutamatergic fibers involved in maintaining posture, initiating locomotion, and/or modulating neuronal circuits and (2) increased neuron counts in the red, reticular, and vestibular nuclei. 29, 30 In contrast, a study by Vasconcelos et al reported that riluzole did not affect swimming velocities; this is likely because swimming does not require body weight support due to buoyancy. 30 Furthermore, some studies indicated that riluzole does not have an impact on BBB locomotor score, upper extremity function, or coordination. 12, 22, 27, 29 Timing and duration of riluzole administration may also be a relevant consideration; specifically, rapid and prolonged treatment enables immediate and continued blockage of glutamatergic excitotoxicity and improved neurobehavioral outcomes. 11, 19 This review also indicated that riluzole may attenuate neuropathic pain and suppress spasticity. Injury to the spinal cord results in hyperalgesia and mechanical allodynia below the level of injury while increasing spontaneous activity at the dorsal horn. 12, 26 These findings were confirmed by increased withdrawal thresholds to innocuous stimuli and an increase in tail flick latency following application of a radiant heat stimuli. 12, 26 Moreover, there was a significant decrease in response to noxious and non-noxious stimuli, including stretch, pinch, and light touch. 24 Riluzole affects these outcomes by modulating glutamatergic excitotoxicity in the dorsal horn. 26 Furthermore, an increase in spontaneous activity may be due to a decrease in inhibitory GABAergic interneurons at the dorsal horn as well as a reduction of descending inhibition from the bulbospinal serotonergic and adrenergic neurons. 12 Longer term changes may also occur, including increased gene transcription of voltage gated sodium channels, causing abnormal physiological responses to peripheral stimulation. Finally, the administration dose may be an important consideration as lower doses of riluzole (eg, 0.8 or 2.5 mg/kg) do not improve sensitivity to innocuous mechanical stimuli. 12 The dose response gradient observed on intracerebroventricular injection of riluzole signifies that the brain (in addition to the peripheral nerves) may also be a key site of riluzole's actions; specifically, it is hypothesized that the ventral posterolateral nucleus of the thalamus may be an important target. 12 Riluzole may also significantly improve gait parameters. In a study by Karadimas et al, surgical decompression was associated with increased blood flow and reperfusion of the spinal cord parenchyma. 33 Reperfusion of the gray matter resulted in chronic and persistent neuronal oxidative damage as well as increased expression of DNA damage repair processes. 33 This study also demonstrated that riluzole can attenuate ischemia reperfusion injury associated with decompression surgery, decrease oxidative damage, and protect against destruction of the mitochondrial membrane. Furthermore, a combination of surgical decompression and riluzole can significantly improve forelimb function and nearly restore a smooth and rhythmic gait pattern. 33 In addition to restoration of motor function, improvement in gait parameters may also reflect a reduction in sensitivity to mechanical stimulation. In a study by Moon et al, rats treated with riluzole had significantly longer contact between the paw and the glass plate. 26 This review provides the background information necessary to interpret the results of clinical trials on the impact of riluzole in traumatic and nontraumatic SCI. Improvements in tissue damage and neurobehavioral outcomes may significantly affect quality of life in these patients.
Strengths and Limitations
This systematic review reflects the first to evaluate the impact of riluzole on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic SCI. Strengths of this review include the following: (1) the search strategy was extensive, (2) 2 reviewers independently evaluated the articles for eligibility, (3) the evidence was assessed using the SYRCLE tool, and (4) the review was formatted using the PRISMA guidelines.
Limitations of this review include the following: (1) studies were excluded if they were not in English and (2) it was challenging to assess certain domains of the SYRCLE tool.
Conclusion
In preclinical models of traumatic and nontraumatic SCI, riluzole significantly improves locomotor scores, gait function, and measures of neuropathic pain. This review provides the background information necessary to interpret the results of clinical trials on the impact of riluzole in traumatic and nontraumatic SCI.
